Access to Quality Assured generic Intramuscular DMPA continues to rise

PT TUNGGAL IDAMAN ABDI, Indonesia, has been awarded a risk category 2 ranking from the WHO Expert Review Panel (see https://www.unfpa.org/resources/reproductive-health-medicines) for its generic intramuscular injectable, medroxyprogesterone acetate depot 150mg/ml, marketed as TRICLOFEM.

This is a major milestone achieved on the pathway to WHO PQ and represents another step towards increasing access to quality assured generic DMPA and addressing the barriers to making this widely used product more readily available to women and girls of need in lower and middle income countries.

Concept Foundation has a long standing partnership with PT Tunggal and warmly congratulates the company on achieving this milestone. Concept has been able to provide support to PT Tunggal towards WHO PQ of its generic DMPA through the generous support of the Bill and Melinda Gates Foundation, through its program entitled “Addressing the barriers to making quality assured, three monthly injectable contraception widely available”.

 

Menu